文献速递胸部CT

特发性肺纤维化患者的CT形态学分析与抗纤维化治疗

Computed tomography morphomics and antifibrotic therapy in idiopathic pulmonary fibrosis.
PubMed 文献 · Clin Radiol · 2024-11-29

单中心回顾性纳入84例接受抗纤维化治疗的特发性肺纤维化患者,分吡非尼酮组、尼达尼布组及吡非尼酮-尼达尼布转换组,用网络形态学分割工具在胸部CT预设椎体层面测量双侧竖脊肌与胸肌的横截面积和密度。三组用力肺活量、一氧化碳弥散量、胸肌横截面积及竖脊肌横截面积均显著下降,肌肉密度无显著变化;治疗前三组间形态学分析存在差异。治疗前BMI低于30的患者中,尼达尼布较吡非尼酮治疗者胸肌横截面积丢失显著更大;三组间用力肺活量与一氧化碳弥散量无差异。

要点

  • 三组抗纤维化治疗后胸肌与竖脊肌横截面积均显著下降,肌肉密度无显著变化。
  • 治疗前BMI低于30者,尼达尼布较吡非尼酮治疗胸肌横截面积丢失显著更大。
  • 三组间用力肺活量与一氧化碳弥散量无差异。

核心结论

  • 整个特发性肺纤维化患者队列中肺功能与形态学参数之间无直接相关性。
  • 不同治疗组之间肌肉体积丢失的速率存在差异,作者认为这是临床医生选择抗纤维化药物时的重要考虑因素。

研究设计与样本

  • 单中心回顾性评估接受抗纤维化治疗的特发性肺纤维化患者,共84例。
  • 按抗纤维化治疗分为吡非尼酮组、尼达尼布组及吡非尼酮-尼达尼布转换组三组。
  • 使用网络形态学分割工具在胸部CT预设椎体层面测量双侧竖脊肌与胸肌的肌肉数量(横截面积,cm²)与质量(密度,Hounsfield Units)。

关键影像表现/征象

  • 三组均显示用力肺活量、一氧化碳弥散量、胸肌横截面积与竖脊肌横截面积统计学显著下降。
  • 肌肉密度无显著变化。
  • 不同治疗组间的分析形态学存在差异。

诊断标准与关键数值

  • 治疗前BMI低于30的患者中,尼达尼布较吡非尼酮治疗者胸肌横截面积丢失显著更大。
  • 三组间用力肺活量与一氧化碳弥散量无差异。

临床应用与阅片要点

  • 作者认为不同治疗组间肌肉体积丢失速率的差异是临床医生选择抗纤维化药物时的重要考虑因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: Idiopathic pulmonary fibrosis (IPF) is a debilitating and fatal lung disease. Changes in body composition potentially correlate with outcomes in patients with IPF.

MATERIALS AND METHODS: Patients with IPF on antifibrotic treatment attending a single institution were identified and retrospectively evaluated (n=84). Three groups were formed based on antifibrotic treatment: pirfenidone group, nintedanib group and pirfenidone-nintedanib switch group. Morphomic analysis of muscle quantity (cross-sectional area in cm2) and quality (density in Hounsfield Units) on thoracic computed tomography (CT) was performed using a web-based morphomic segmentation tool. Bilateral erector spinae and pectoralis muscles were measured at pre-defined vertebral levels.

RESULTS: All three treatment groups showed a statistically significant decline in forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO), pectoral muscle cross sectional area (PMA), and erector spinae muscle cross-sectional area (ESMA). Muscle density did not change significantly. Differences existed in analytic morphomics between treatment groups. Patients with a pretreatment body mass index (BMI) below 30 were found to have a significantly greater loss of PMA when treated with nintedanib instead of pirfenidone. FVC and DLCO did not differ between treatment groups.

CONCLUSION: There were no direct correlations between pulmonary function and morphomic parameters in our entire group of IPF patients. However, between different treatment groups, the rate of muscle bulk loss differed. This is an important consideration for clinicians when deciding on an antifibrotic agent of choice.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. O'Mahony AT, Waldron MG, Henry PJ, et al. Computed tomography morphomics and antifibrotic therapy in idiopathic pulmonary fibrosis. Clin Radiol. 2024. PMID: 39709732. doi:10.1016/j.crad.2024.106759

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。